Women and Infants Transmission Study IV - Chicago

描述(申请者提供)：妇幼传播研究 (WITS)是一项全国性、多中心、纵向观察队列研究 已经登记的感染HIV-1的孕妇和她们的婴儿， 在过去的十年里。这项研究的总体目标是了解 孕妇和婴儿、儿童和青少年中的艾滋病毒-I感染， 以及抗逆转录病毒的过程、反应、挑战和副作用 心理治疗。本申请是WITS IV领导力和研究议程 申请，将由六个不同的临床站点提供支持 申请。领导力和研究议程将确定研究目标， WITS的理由、研究结构和研究方法IV.原则 申请的调查员将担任WITS执行委员会主席 机智的管理机构。 WITS IV的具体目标包括：一、界定艾滋病毒的自然历史--L 抗逆转录病毒时代的婴儿、儿童和青少年感染 治疗(ART)；2.确定接触辐射的直接和长期影响 未感染的胎儿、婴儿、儿童和青少年的抗逆转录病毒治疗；3.确定 妊娠期间登记的HIV-I感染妇女的自然病史 艺术的时代；4.审视对艺术的坚持与 药物治疗，出现对抗逆转录病毒药物的抗药性，以及临床和 儿科患者及其母亲的治疗结果；5.确定 艾滋病病毒感染者丙型肝炎病毒的发病机制和自然病史及HIV-L/丙型肝炎病毒混合感染 受感染的孕妇，以确定新感染丙型肝炎病毒的妇女队列， 并检查导致丙型肝炎病毒从 母亲给她们的婴儿。这个应用程序将建立在 WITS 1-111研究#年艾滋病毒-L感染的变化格局 不断增强的艺术力量。它将有助于深入了解 围产期艾滋病毒-L感染的新时代及其带来的后果和挑战 预防和治疗感染的治疗。

DESCRIPTION (provided by applicant): The Women and Infants Transmission Study (WITS) is a national, multi-center, longitudinal observational cohort study ofHIV-1 infected pregnant women and their infants that has been enrolling, patients for the last decade. The overall goal of the study is to understand HIV -I infection in pregnant women and in infants, children and adolescents, and the course, response, challenges, and side effects of antiretroviral therapy. This application is the WITS IV Leadership and Research Agenda application, which will be supported by six separate clinical site applications. The Leadership and Research Agenda will define the study aims, justification, study structure, and study approach for WITS IV. The Principle Investigator of the application will chair the WITS Executive Committee, the governing body of WITS. The Specific Aims for WITS IV include I. To define the natural history of HIV-l infection in infants, children, and adolescents in an era of anti-retroviral therapy (ART); 2. To determine the immediate and late effects of exposure to ART in uninfected fetuses, infants, children, and adolescents; 3. To define the natural history of HIV-I infected women enrolled during pregnancy in the era of ART; 4. To examine the relationships between adherence to ART medication, emergence of HIV-I resistant to ART, and the clinical and treatment outcome in pediatric patients and their mothers; 5. To define the pathogenesis and natural history of HCV and HIV-l/HCV co-infection in HIV-l infected pregnant women, to identify a cohort of women with new HCV infection, and to examine the factors responsible for the transmission of HCV from mothers to their infants. This application will build on the studies done in WITS 1-111 to examine the changing landscape of HIV-l infection in eras of increasing potency of ART. It will contribute to an in-depth understanding of the new era of perinatal HIV-l infection and the consequence and challenges of therapy to prevent and treat the infection.